Dr Solomon Mequanente Abay 

Ethiopia

EDCTP portfolio: Clinical Research & Development Fellowships

Dr Solomon Mequanente Abay broadened his knowledge of clinical trial operations, ethics review and regulatory aspects at the Novartis Institute of Biomedical Research.

Upgrading postgraduate clinical research curricula of the CDT-Africa

This fellowship aimed to support the fellow to acquire skills in clinical research and development through placement at the Novartis Institutes for Biomedical Research (NIBR).

The challenge

To improve his theoretical and practical capabilities in clinical trials, Dr Abay completed advanced training organised by NIBR. The assigned courses included advanced GCP, clinical trial monitoring, pharmacokinetic analysis, data management, clinical trials project management, and working practices and SOPs.

Dr Abay was also engaged in phase I and phase II clinical trials. The work included reviewing clinical trials protocols and preparation of clinical study reports. He also conducted remote monitoring and site co-monitoring of company-sponsored studies.

During the reintegration phase of the fellowship at Addis Ababa University, a clinical research protocol template was developed to support researchers in developing protocols with the appropriate content and correct format for submission to the institutional review board and the regulatory authority. Similarly, he supported faculties at the University of Addis Ababa in their efforts to strengthen the phase I clinical trial centre and its side laboratory. He also organised a two-day national training workshop on medicine development and regulation. At the same time, Dr Abay was assigned to be a member and the secretary of the institutional review board of the College of Health Sciences at the Addis Ababa University.

The project

At Novartis, Dr Abay broadened his knowledge of clinical trial operations, ethics review processes and regulatory authority functions. In his home institution at Addis Ababa University, he shared his clinical research skills by training postgraduate students and collaborated with the university and other national institutions to improve clinical research management. As a member and secretary of the institutional review board, he reviews clinical research protocols and is involved in the follow-up of clinical studies. Furthermore, Dr Abay contributed to reviewing curricula of postgraduate programs involving clinical research which will be hosted at the Center for Innovative Drug Development & Therapeutic Trials for Africa (CDT-Africa).

Impact


test the safety and efficacy of this new formulation in young children

Bringing antiretroviral drugs to children

The CHAPAS trials have ensured that many more children with HIV have benefited
from life-saving antiretrovirals.

EDCTP portfolio: HIV & HIV-associated infections

The challenge

This fellowship aimed to support the fellow to acquire skills in clinical research and development through placement at the Novartis Institutes for Biomedical Research (NIBR).

To improve his theoretical and practical capabilities in clinical trials, Dr Abay completed advanced training organised by NIBR. The assigned courses included advanced GCP, clinical trial monitoring, pharmacokinetic analysis, data management, clinical trials project management, and working practices and SOPs.

Dr Abay was also engaged in phase I and phase II clinical trials. The work included reviewing clinical trials protocols and preparation of clinical study reports. He also conducted remote monitoring and site co-monitoring of company-sponsored studies.

During the reintegration phase of the fellowship at Addis Ababa University, a clinical research protocol template was developed to support researchers in developing protocols with the appropriate content and correct format for submission to the institutional review board and the regulatory authority. Similarly, he supported faculties at the University of Addis Ababa in their efforts to strengthen the phase I clinical trial centre and its side laboratory. He also organised a two-day national training workshop on medicine development and regulation. At the same time, Dr Abay was assigned to be a member and the secretary of the institutional review board of the College of Health Sciences at the Addis Ababa University.

The project

The later CHAPAS-3 trial compared the efficacy and safety of three fixed-dose combinations including two without stavudine (found to have some long-term side effects in adults, leading to a recommendation that its use be discontinued in children). The trial the first of its kind in Africa studied nearly 500 children at four sites in two African countries.

At Novartis, Dr Abay broadened his knowledge of clinical trial operations, ethics review processes and regulatory authority functions. In his home institution at Addis Ababa University, he shared his clinical research skills by training postgraduate students and collaborated with the university and other national institutions to improve clinical research management. As a member and secretary of the institutional review board, he reviews clinical research protocols and is involved in the follow-up of clinical studies. Furthermore, Dr Abay contributed to reviewing curricula of postgraduate programs involving clinical research which will be hosted at the Center for Innovative Drug Development & Therapeutic Trials for Africa (CDT-Africa).

ratios forfixed-dose combinations and on appropriatedosage according to weight. 

The CHAPAS-3 trial confirmed the effectiveness of fixed-dose combinations, providing further impetus to the rollout of antiretrovirals to children. Its evidence on abacavir informed the WHO recommendation of abacavir-containing combinations for first-line therapy in children. Trial data have also been used to support applications for regulatory approval for new scored efavirenz tablets.

Impact

L’homme RF et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS. 2008;22(5):557–65.

Mulenga V et al. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIVinfected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. Lancet Infect Dis. 2016;16(2):169–79.

WHO. Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2010.

WHO. Consolidated guidelines on the use of antiretroviral drugs
for treating and preventing

HIV infection: Recommendations for a public health approach
(second edition). 2016

Projects: Children with HIV in Africa Pharmacokinetics and Adherence of Simple Antiretroviral Regimens (CHAPAS): CHAPAS-1 and -3

Project lead: Professor Chifumbe Chintu, University Teaching Hospital, Zambia (CHAPAS-1); Dr Veronica Mulenga, University Teaching Hospital, Zambia (CHAPAS-3)

Target population(s): Children with HIV

Sample size: 71 (CHAPAS-1); 480 (CHAPAS-3)

Countries involved: Ireland, the Netherlands, the UK, the USA, Zambia (CHAPAS-1); Uganda, Zambia (CHAPAS-3)

Project duration: 2005–2009 (CHAPAS-1); 2010 –2011 (CHAPAS-3)

EDCTP funding: €1.2M (CHAPAS-1); €4.6M (CHAPAS-3)

Total project funding: €1.2M (CHAPAS-1); €5.0M

About us

The European & Developing Countries Clinical Trials Partnership (EDCTP) is a public–public partnership between 14 European and 16 African countries, supported by the European Union. EDCTP’s vision is to reduce the individual, social and economic burden of poverty-related infectious diseases by affecting sub-Saharan Africa. EDCTP’s mission is to accelerate the development of new or improved medicinal products for the identification, treatment and prevention of infectious diseases, including emerging and re-emerging diseases, through pre- and postregistration clinical studies, with emphasis on phase II and III clinical trials. Our approach integrates conduct of research with development of African clinical research capacity and networking. The second EDCTP programme is implemented by the EDCTP Association supported under Horizon 2020, the European Union’s Framework Programme for Research and Innovation.

Contact us

For more information, please contact us or leave a message using this form.
Please enter your name
Please enter a correct e-mail address
Please enter a comment
Thank you! Your message has been sent.
Something went wrong while submitting the form. Try again.

Share this publication

Forward this page by e-mail or share it directly on social media.

Search

Enter a search term to search the EDCTP publications.
Minimal length to search is 3 characters

This publication uses cookies

We use functional and analytical cookies to improve our website. In addition, third parties place tracking cookies to display personalised advertisements on social media. By clicking accept you consent to the placement of these cookies.